Sonova Holding AG, a leading Swiss manufacturer of hearing systems, has solidified its position as a technology pioneer, ranking top in the Swiss Innovation Ranking for the second consecutive year and 12th in Europe, driven by its commitment to prod…

Universal Health Services, Inc. (UHS) faces a potential financial and reputational hit after a multi-million dollar jury verdict for allegedly poaching clinical staff, which could impact its earnings and market perception.

A recent report by Veeva Systems Inc. highlights significant inefficiencies in clinical data management, with two-thirds of clinical data managers and CRAs citing these issues as a risk to data quality, and automation of data management processes be…

AbbVie Inc. has announced a series of strategic initiatives to expand its therapeutic portfolio, improve operational efficiency, and navigate market-driven pricing strategies, positioning the company for sustained growth in the biopharmaceutical sec…

Biogen Inc. has secured regulatory approval in China for its investigational Alzheimer’s therapy, LEQEMBI, marking a significant milestone for the company’s Alzheimer’s portfolio and positioning it to capture a share of the growing market in China.

Shanghai Fosun Pharmaceutical Group Co Ltd has announced a strategic divestment of its stake in Shanghai Clon, a move aimed at sharpening its focus on core drug development and optimizing asset allocation in a dynamic healthcare market.

Molina Healthcare Inc. has received a favorable assessment from investment research firm Bernstein, maintaining a ‘Buy’ rating and revising its price target to $220 per share, citing the company’s ability to generate sustainable returns in a competi…

HCA Healthcare Inc. maintains a strong financial position, with a robust earnings trajectory and efficient cost management, while also investing in strategic initiatives such as workforce development and digital transformation to drive future growth…

Siemens Healthineers AG, a leading medical technology company, is navigating uncertainty due to potential US tariffs on medical products, which has led to a decline in its share price and raised concerns about its revenue and margins.

Fresenius SE & Co KGaA, a German healthcare conglomerate, faces short-term market headwinds due to broader sector volatility, but its robust fundamentals and proactive risk management position it for long-term success.